| Johnny Makhoul, MD | |
|
1301 Pleasant Valley Rd, Suite 202, Owensboro, KY 42303-9774 | |
| (270) 417-7500 | |
| (270) 417-7509 |
| Full Name | Johnny Makhoul |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 38 Years |
| Location | 1301 Pleasant Valley Rd, Owensboro, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831183714 | NPI | - | NPPES |
| 200056020B | Medicaid | IN | |
| 64309420 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 30942 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Owensboro Health Regional Hospital | Owensboro, KY | Hospital |
| Ohio County Hospital | Hartford, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Owensboro Health Medical Group Inc | 0648255034 | 358 |
News Archive
A $250,000 grant from the Centers for Disease Control and Prevention (CDC) will support a Rhode Island Hospital research study aimed at reducing the state's leading cause of accidental death among adults. Researchers will explore the use and effectiveness of statewide prescription monitoring programs (PMP) in reducing the number of accidental overdose deaths involving prescription opioids like OxyContin and Vicodin in both Rhode Island and Connecticut.
Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with the Salk Institute for Biological Studies to provide its researchers with the LEAP™ Cell Processing Workstation.
Anticholinergics are a class of medications that are often prescribed for allergies, lung disease, and urinary incontinence. They also often can increase health risks for older adults.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.
Bioheart, Inc. announced today that Bioheart's primary focus is on completing clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.
› Verified 4 days ago
| Entity Name | Owensboro Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235518242 PECOS PAC ID: 0648255034 Enrollment ID: O20040621000818 |
News Archive
A $250,000 grant from the Centers for Disease Control and Prevention (CDC) will support a Rhode Island Hospital research study aimed at reducing the state's leading cause of accidental death among adults. Researchers will explore the use and effectiveness of statewide prescription monitoring programs (PMP) in reducing the number of accidental overdose deaths involving prescription opioids like OxyContin and Vicodin in both Rhode Island and Connecticut.
Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with the Salk Institute for Biological Studies to provide its researchers with the LEAP™ Cell Processing Workstation.
Anticholinergics are a class of medications that are often prescribed for allergies, lung disease, and urinary incontinence. They also often can increase health risks for older adults.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.
Bioheart, Inc. announced today that Bioheart's primary focus is on completing clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Johnny Makhoul, MD Po Box 23229, Owensboro, KY 42304-3229 Ph: (270) 688-1330 | Johnny Makhoul, MD 1301 Pleasant Valley Rd, Suite 202, Owensboro, KY 42303-9774 Ph: (270) 417-7500 |
News Archive
A $250,000 grant from the Centers for Disease Control and Prevention (CDC) will support a Rhode Island Hospital research study aimed at reducing the state's leading cause of accidental death among adults. Researchers will explore the use and effectiveness of statewide prescription monitoring programs (PMP) in reducing the number of accidental overdose deaths involving prescription opioids like OxyContin and Vicodin in both Rhode Island and Connecticut.
Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with the Salk Institute for Biological Studies to provide its researchers with the LEAP™ Cell Processing Workstation.
Anticholinergics are a class of medications that are often prescribed for allergies, lung disease, and urinary incontinence. They also often can increase health risks for older adults.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.
Bioheart, Inc. announced today that Bioheart's primary focus is on completing clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.
› Verified 4 days ago
David B. Olalekan, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1201 Pleasant Valley Rd, Owensboro, KY 42303 Phone: 270-417-4700 Fax: 270-417-4709 | |
Dr. Jacob S. Hodskins, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 Breckenridge St, Suite 400, Owensboro, KY 42303 Phone: 270-688-3445 Fax: 270-688-3344 | |
Dr. Adrian James Yeiser, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 811 E Parrish Ave, Owensboro, KY 42303 Phone: 270-688-3371 Fax: 270-688-3370 | |
Dr. Roshan K. Mathew, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3110 Fairview Dr, Owensboro, KY 42303 Phone: 270-240-2129 | |
Madison P Hardesty, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1201 Pleasant Valley Rd, Owensboro, KY 42303 Phone: 270-417-4700 Fax: 270-417-4709 | |
Dr. David M Brey, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 Breckenridge St Ste 303, Owensboro, KY 42303 Phone: 270-688-5100 Fax: 270-688-5109 | |
Mahesh K. Moolani, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1200 Breckenridge St, Owensboro, KY 42303 Phone: 270-685-8224 Fax: 270-685-8228 |